SLS - SELLAS Life Sciences Group, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD

SELLAS Life Sciences Group, Inc.

15 West 38th Street
10th Floor
New York, NY 10018
United States
917-435-4353
http://www.sellaslifesciences.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees8

Key Executives

NameTitlePayExercisedYear Born
Dr. Angelos M. Stergiou M.D., ScD h.c.Founder, Vice Chairman, Pres & CEON/AN/AN/A
Mr. Martin G. BaumChief Operating OfficerN/AN/A1966
Mr. John Thomas BurnsVP of Fin., Corp. Controller & Interim Principal Accounting OfficerN/AN/A1985
Ms. Barbara A. WoodExec. VP, Gen. Counsel & Corp. Sec.N/AN/A1963
Dr. Nicholas J. SarlisChief Medical Officer & Sr. VPN/AN/AN/A
Amounts are as of and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

SELLAS Life Sciences Group, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications. The company's lead product candidate is galinpepimut-S (GPS), a wilms tumor 1 targeting peptide-based cancer immunotherapeutic agent, which has completed Phase II clinical trials for the treatment of acute myeloid leukemia and malignant pleural mesothelioma; is in Phase II clinical trials to treat multiple myeloma; and is in various development phases as a potential treatment for ovarian cancer. It also develops NeuVax that is in Phase II clinical trials for the treatment of breast cancer; GALE-301 and GALE-302, which have completed early stage trials in ovarian, endometrial, and breast cancers; and GALE-401, an anagrelide controlled release that has completed Phase II clinical trials in patients with essential thrombocythemia, as well as for the treatment of elevated platelets in patients with myeloproliferative neoplasms. The company has strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; and Advaxis, Inc. on a research program to evaluate, through a proof of principle trial, a clinical candidate, which comprises the combination of proprietary Lm-based antigen delivery technology and GPS. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York.

Corporate Governance

SELLAS Life Sciences Group, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.